CompanyGraph
Siemens Healthineers AG
0PMJ · Germany
siemens-healthineers.comFinancials as of FY2022 · latest on file
Sells MRI scanners and radiation therapy machines that only work properly when used together.
- Depends onDownstream position: depends on 8 industries, supplies 3
- Interpretations3 currently firing — 1 · 2
What this company is and how it runs — written from structure, not news.
Siemens Healthineers builds the imaging and radiation therapy systems that run cancer treatment in sequence: a superconducting magnet, cooled with liquid helium at factories in Erlangen and Shanghai, generates the electromagnetic field that Siemens' own reconstruction algorithms are calibrated against, and those algorithms produce the tumor maps that Varian's treatment planning software then uses to write each patient's radiation beam protocol. Because the radiation protocol is computed from Siemens image coordinates, a hospital cannot swap out the scanner or the linear accelerator mid-treatment without the oncology team replanning the patient's entire radiation course from scratch — and with years of patient archives already stored in that coordinate space, the practical cost of switching is high enough that most hospitals stay on the platform. The same chain that locks customers in also has two points where it can break: helium shortages can halt magnet assembly entirely, since no substitute exists for the liquid helium that keeps the magnets superconducting, and if U.S.-China export controls cut off the advanced chips running the AI reconstruction layer, the calibrated handoff to Varian collapses and the integrated workflow becomes two disconnected, ordinary products.
How does this company make money?
The company sells MRI, CT, and linear accelerator systems as large one-time purchases, with hospitals typically replacing equipment every ten to fifteen years. On top of those sales, it collects recurring fees through service and maintenance contracts, charges software licensing fees for AI diagnostic features, and sells consumables such as helium refills and radiation therapy accessories that customers need to keep the equipment running.
What makes this company hard to replace?
Hospitals have built up years of patient scan archives that are optimized for Siemens reconstruction algorithms — migrating that data to a different scanner system would require retraining clinical staff and validating that old records still read correctly. On top of that, every patient already receiving radiation therapy has a treatment plan stored in Varian's system using Siemens image coordinates. Switching to a competing scanner mid-treatment means the oncology team must replan that patient's entire radiation protocol from the beginning.
What limits this company?
Liquid helium controls how many MRI scanners can be built and tested. Superconducting magnets must be kept extremely cold, and liquid helium is the only thing that keeps them cold enough. When global helium supplies run short, assembly lines at Erlangen and Shanghai stall, because there is no substitute that works.
What does this company depend on?
Liquid helium suppliers to keep MRI magnets cold enough to function. Rare earth element suppliers whose materials go into building those magnets. Varian's TrueBeam linear accelerator technology license, without which the radiation therapy side of the system cannot operate. FDA 510(k) clearances for each scanner model sold in the United States. DICOM protocol compliance to connect scanners to hospital record systems.
Who depends on this company?
Mayo Clinic and similar academic medical centers would lose the real-time AI diagnostic workflows that process patient imaging data as scans are taken. Radiation oncology centers running Varian machines would face treatment delays if Siemens stopped providing linear accelerator maintenance and software updates. Hospital radiology departments would lose access to the Teamplay digital health platform, which they use to monitor equipment performance remotely.
How does this company scale?
The AI algorithms get sharper as more scanners are used around the world, because a larger global installed base produces more imaging data to train on — so the software improves without building new factories. What does not get easier as the company grows is manufacturing: helium handling and the precision assembly of superconducting magnets cannot be fully automated, so adding production volume still requires adding skilled labor and helium supply.
What external forces can significantly affect this company?
U.S.-China export restrictions on advanced semiconductor components could cut off the chips that run AI reconstruction inside scanner hardware. The European Union's Medical Device Regulation requires extensive clinical proof before AI diagnostic features can be approved, slowing how fast new software can reach patients. Aging populations in wealthier countries are driving more demand for imaging, but hospital budgets are under pressure, which makes large capital purchases harder to approve.
Where is this company structurally vulnerable?
If U.S.-China export controls cut off access to the advanced semiconductor chips that run the AI reconstruction inside Siemens scanners, the algorithm layer would stop working. Without those algorithms, the tumor maps degrade, the handoff to Varian treatment planning breaks down, and the two halves of the system — imaging and radiation therapy — become disconnected products that hospitals could replace separately with cheaper alternatives.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Close In Upper Portion Of Recent Range, Bollinger Bands, And RSI
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
As of FY2022 (year ended June 30, 2022). Newer annual figures aren't yet on file.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Two cash observations have aligned: the cash ratio (cash divided by current liabilities) is in the upper industry-benchmarked range, and cash represents a meaningful share of total assets.
Liquidity Ratios Elevated
Three liquidity ratios co-occur in their elevated ranges: current ratio (industry-benchmarked), quick ratio, and cash ratio. The simultaneous firing means coverage is elevated through progressively more liquid asset layers, not concentrated in inventory or receivables.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.